COVID-19 infection
Conditions
Interventions
Control group:Malt date tea
Experimental group:Malt date tea and liushen pill
Sponsors
The Fifth People's Hospital of Suzhou
Eligibility
Sex/Gender
All
Age
14 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >=14; Men and women; 2. Novel Coronavirus mild or normal infection (the diagnostic criteria are in accordance with the Novel Coronavirus Diagnosis Protocol for Pneumonia (Trial Version ix) issued by the NHC, or if updated, in accordance with the new version of the Diagnosis Protocol), or asymptomatic infection of novel Coronavirus nucleic acid positive within 5 days of the onset of the disease; 3. Subjects voluntarily participate in the study and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Respiratory tract infection caused by primary immunodeficiency disease, acquired immunodeficiency syndrome, congenital respiratory malformation, congenital heart disease, gastroesophageal reflux disease, abnormal lung development and other basic diseases, with clear evidence of bacterial infection; 2. Subjects with asthma requiring daily treatment, any other chronic respiratory diseases, respiratory bacterial infections such as suppurative tonsillitis, acute tracheal bronchitis, sinusitis, otitis media and other respiratory diseases affecting clinical trial evaluation.Chest CT confirmed the presence of severe interstitial lung disease, bronchiectasis and other basic lung diseases; 3. Severe pneumonia requiring mechanical ventilation; 4. As determined by the investigator, the patient has a pre-existing or current medical condition that may affect his participation in the study or affect the outcome of the study, including malignant disease, autoimmune disease, liver and kidney disease, hematologic disease, neurological disease, and endocrine disease; Having a disease that seriously affects the immune system, such as HIV infection, or blood system, or splenectomy or organ transplantation; 5. Pregnant or lactating women; 6. Patients who have participated in other clinical trials within the past 1 month; 7. Allergic constitution, such as the history of allergic to two or more drugs or food, or known allergies to the drug ingredients; 8. The researcher considers that there are any factors that are not suitable for inclusion or affect the efficacy evaluation of the subjects.Random grouping method.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to lift quarantine (asymptomatic infection, mild);Length of hospital stay (general);Time when the main symptoms disappeared (fever, limb pain, pharyngeal discomfort); | — |
Secondary
| Measure | Time frame |
|---|---|
| The decrease in viral nucleic acid load (ORF or N);COVID-19 serum specific antibodies (IgG, IgM);TCM syndrome scale score;Chest CT; | — |
Countries
China
Contacts
Public ContactJianping Zhang
The Fifth People's Hospital of Suzhou
Outcome results
None listed